Drug profile · INN
insulin aspart protamine recombinant
NOVOLOG MIX 50/50
insulin aspart protamine recombinant (NOVOLOG MIX 50/50) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — insulin aspart protamine recombinant
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
insulin aspart protamine recombinant (NOVOLOG MIX 50/50) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is insulin aspart protamine recombinant?
insulin aspart protamine recombinant (NOVOLOG MIX 50/50) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for insulin aspart protamine recombinant?
NOVOLOG MIX 50/50 is a marketed brand name for insulin aspart protamine recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin aspart protamine recombinant?
insulin aspart protamine recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.